Fierce Pharma

JUNE 1, 2024

After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower express | After Enhertu pioneered the HER2-low category in breast cancer treatment, AstraZeneca and Daiichi Sankyo are now hopeful that the antibody-drug conjugate can reach tumors with an even lower expression of the protein biomarker.

Antibody 123

Antibody Protein Drugs 123

Drug Patent Watch

JUNE 1, 2024

Brivaracetam is the generic ingredient in two branded drugs marketed by Ucb Inc, Aurobindo Pharma Ltd, Lupin Ltd, Sunshine, and Zydus Pharms and, and is included in seven NDAs.

Drugs 59

Drugs Branding Marketing 59

Fierce Pharma

JUNE 1, 2024

Almost 10 years ago, Merck ushered superstar cancer drug Keytruda across the FDA finish line for the first time, starting down a path that would ultimately yield dozens of additional approvals | The Inflation Reduction Act's price negotiation measures stand to cut down drug candidates before they can "grow roots" later in development, Eli Lilly CEO David Ricks said during a panel discussion.

Drugs 108

Drugs Development 108

Drug Patent Watch

JUNE 1, 2024

Dabigatran etexilate mesylate is the generic ingredient in two branded drugs marketed by Alkem Labs Ltd, Apotex, Hetero Labs Ltd Iii, and Boehringer Ingelheim and, and is included in five… Source

Drugs 59

Drugs Branding Marketing 59

Advertisement

Clinical Supply

Fierce Pharma

JUNE 1, 2024

Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that the o | Armed with two positive phase 3 trial readouts and the hope that at least one will show a significant patient survival benefit, GSK thinks it has the data to convince doctors and the FDA that its once-failed antibody-drug conjugate Blenrep can work in multiple myeloma.

Doctors 90

Doctors Doctor Antibody Trials 90

Drug Patent Watch

JUNE 1, 2024

Annual Drug Patent Expirations for NUZYRA Nuzyra is a drug marketed by Paratek Pharms Inc and is included in two NDAs. It is available from one supplier.

Drugs 59

Drugs Marketing 59